MARKET

CDXC

CDXC

Chromadex Corp
NASDAQ
3.070
-0.120
-3.76%
After Hours: 3.070 0 0.00% 19:25 07/26 EDT
OPEN
3.190
PREV CLOSE
3.190
HIGH
3.280
LOW
3.040
VOLUME
271.01K
TURNOVER
0
52 WEEK HIGH
4.650
52 WEEK LOW
1.250
MARKET CAP
231.90M
P/E (TTM)
-65.3191
1D
5D
1M
3M
1Y
5Y
1D
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively To Health Care Practitioners
1health ChromaDex Corp. Launches the Niagen+ NAD+ Test Kit. The at-home test kit is now available exclusively through the company's healthcare practitioner channel. The test kit provides a reliable method for measuring patient blood NAD+ levels. Results are available to HCPs and their patients.
Benzinga · 3d ago
CHROMADEX APPOINTS CARLOS LOPEZ AS SENIOR VICE PRESIDENT, GENERAL COUNSEL
Reuters · 4d ago
Weekly Report: what happened at CDXC last week (0715-0719)?
Weekly Report · 4d ago
Executive reshuffles: Otis Worldwide, HSBC and Rockwell Automation in focus
Executive reshuffles: Otis Worldwide, HSBC and Rockwell Automation in focus. Several Wall Street executives stepped up for new roles as part of leadership reshuffling. Some companies added new positions to steer growth prospects such as Otis worldwide, HSBC, ROK and Glencore.
Seeking Alpha · 07/19 18:40
ChromaDex appoints James Lee as interim CFO
ChromaDex appoints James Lee as interim CFO. Lee takes over the positions after Brianna Gerber resigned from her roles. ChromaDex Corporation (CDXC) stock is down 1.7% to $8.05 in pre-market trading.
Seeking Alpha · 07/17 10:39
Chromadex Says Board Appointed James Lee As Interim CFO
Benzinga · 07/16 20:15
CHROMADEX CORP: BOARD APPOINTED JAMES LEE AS CO'S INTERIM CHIEF FINANCIAL OFFICER
Reuters · 07/16 20:13
ChromaDex To Ship Pharmaceutical-Grade Intravenous and Injectable Niagen At Wellness Clinics In August
Benzinga · 07/16 12:38
More
About CDXC
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.

Webull offers Chromadex Corp stock information, including NASDAQ: CDXC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CDXC stock methods without spending real money on the virtual paper trading platform.